TNFα antagonists in rheumatoid arthritis patients seen in everyday practice

Joint Bone Spine

Volumn 74, Issue 6, 2007, Pages 523-526

  Falgarone, Géraldine ^a   Duclos, Muriel ^a   Boissier, Marie Christophe ^a  

^a INSERM   (France)

Author keywords

Everyday practice; Real world practice; Rheumatoid arthritis; TNF antagonists

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; DECISION MAKING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; HEPATITIS; HUMAN; INFECTION; REMISSION; RHEUMATOID ARTHRITIS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; DOSE RESPONSE; DRUG COMBINATION; HOSPITALIZATION; MEDICAL SOCIETY; METABOLISM; NOTE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RHEUMATOLOGY; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 37048999583     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.10.002     Document Type: Editorial

References (35)

1. Kvalvik A., Lefsaker L., Dyvik S., et al. Anti tumour necrosis factor-alpha therapy in the ordinary clinical setting. Three-year effectiveness in patients with rheumatoid arthritis. Joint Bone Spine 74 (2007) 606-611
2. St Clair E.W., van der Heijde D.M., Smolen J.S., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50 (2004) 3432-3443
3. Klareskog L., van der Heijde D., de Jager J.P., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
4. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
5. Smolen J.S., Aletaha D., Koeller M., et al. New therapies for treatment of rheumatoid arthritis. Lancet (2007) 10.1016/S0140-6736(07)60784-3
6. Gartlehner G., Hansen R.A., Jonas B.L., et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33 (2006) 2398-2408
7. Sokka T., and Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 48 (2003) 313-318
8. Zink A., Strangfeld A., Schneider M., et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54 (2006) 3399-3407
9. Duclos M., Gossec L., Ruyssen-Witrand A., et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 33 (2006) 2433-2438
10. Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 1075-1086
11. Kristensen L.E., Saxne T., Nilsson J.A., et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8 (2006) R174
12. Wendling D., Materne G.E., Michel F., et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 72 (2005) 309-312
13. Finckh A., Simard J.F., Gabay C., et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65 (2006) 746-752
14. Brocq O., Plubel Y., Breuil V., et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha. Presse Med 31 (2002) 1836-1839
15. Landewe R., van der Heijde D., van der Linden S., et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 65 (2006) 637-641
16. Matsui T., Kuga Y., Kaneko A., et al. Disease activity score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 66 (2007) 1221-1226
17. Vander Cruyssen B., Van Looy S., Wyns B., et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 8 (2006) R112
18. Hyrich K.L., Lunt M., Watson K.D., et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56 (2007) 13-20
19. Iannone F., Trotta F., Montecucco C., et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 66 (2007) 249-252
20. Winthrop K.L. Serious infections with antirheumatic therapy: are biologicals worse?. Ann Rheum Dis 65 Suppl. 3 (2006) iii54-iii57
21. Dixon W.G., Watson K., Lunt M., et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 2368-2376
22. Salliot C., Gossec L., Ruyssen-Witrand A., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46 (2007) 327-334
23. Dixon W.G., Symmons D.P., Lunt M., et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56 (2007) 2896-2904
24. Fautrel B., Constantin A., Morel J., et al. Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. Joint Bone Spine 73 (2006) 433-441
25. Askling J., and Group ftAS. Increased long-term risk for tuberculosis following treatment with TNF-antagonists. The Swedish experience 1999-2006. Ann Rheum Dis 66 Suppl. II (2007) ABS: 162.
26. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1740-1751
27. Askling J., Fored C.M., Baecklund E., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1414-1420
28. Hyrich K.L., Symmons D.P., Watson K.D., et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British rSociety for Rheumatology Biologics Register. Arthritis Rheum 54 (2006) 1786-1794
29. Fautrel B., Woronoff-Lemsi M.C., Ethgen M., et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. Joint Bone Spine 72 (2005) 550-556
30. Reddy J.G., and Loftus Jr. E.V. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 35 (2006) 837-855
31. Hyrich K.L., Symmons D.P., Watson K.D., et al. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 54 (2006) 2701-2702
32. Askling J., and for the ARTIS study group. No increase in overall risk for cancer in RA treated with TNF-antagonists, but risks for certain cancer types may be elevated. Ann Rheum Dis 66 Suppl. II (2007) 54
33. Yang K., Xie G., Zhang Z., et al. Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust N Z J Psychiatry 41 (2007) 266-273
34. Buch M.H., Marzo-Ortega H., Bingham S.J., et al. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals. Rheumatology (Oxford) 43 (2004) 243-244
35. Botsios C., Furlan A., Ostuni P., et al. Effects of low-doses etarnecept in maintaining DAS-remission previously achieved with standard-dose in patients with rheumatoid arthritis. Ann Rheum Dis 66 Suppl. II (2007) ABS: 54